中国女性患者溴隐亭阴道给药治疗高催乳素血症有效性和安全性的Meta分析

2018-10-19 05:11:37袁洪波张伶俐杨春松刘砚韬
中国药房 2018年1期
关键词:Meta分析安全性有效性

袁洪波 张伶俐 杨春松 刘砚韬

中圖分类号 R984 文献标志码 A 文章编号 1001-0408(2018)01-0111-06

DOI 10.6039/j.issn.1001-0408.2018.01.28

摘 要 目的:系统评价中国女性患者溴隐亭阴道给药治疗高催乳素血症的有效性和安全性,为临床提供循证参考。方法:计算机检索PubMed、The Cochrane Liabrary、Excerpta Media Database、中国期刊全文数据库(CJFD)、万方数据库、中国生物医学文献数据库(CBMdisc),收集中国女性患者采用溴隐亭口服片阴道给药(试验组)对比溴隐亭口服给药(对照组)治疗高催乳素血症的随机对照试验(RCT)。对符合纳入标准的研究提取资料并按照Cochrane 系统评价员手册5.1.0评价纳入研究的方法学质量后,采用Rev Man 5.1统计软件对血清泌乳素(PRL)水平、月经改善率、妊娠恢复率、溢乳消失率、消化道不良反应发生率、神经系统不良反应发生率指标进行Meta分析。结果:共纳入16项RCT,合计1 175例患者。Meta分析结果显示,试验组患者消化道不良反应发生率[OR=0.14,95%CI(0.09,0.23),P<0.001]、神经系统不良反应发生率[OR=0.32,95%CI(0.11,0.90),P=0.03]显著低于对照组,差异均有统计学意义;两组患者血清PRL水平[MD=0.24,95%CI(-0.94,1.41),P=0.69]、月经改善率[RD=0.04,95%CI(-0.04,0.11),P=0.32]、妊娠恢复率[RD=0.01,95%CI(-0.08,0.10),P=0.84]、溢乳消失率[RD=0.05,95%CI(-0.03,0.13),P=0.20]比较,差异均无统计学意义。结论:溴隐亭阴道给药与口服给药相比,在疗效方面无显著差异,在消化道不良反应率、神经系统不良反应率方面存在明显优势,安全性更高,建议开发阴道给药的溴隐亭制剂。

关键词 溴隐亭;阴道给药;口服给药;系统评价;有效性;安全性;Meta分析

ABSTRACT OBJECTIVE: To evaluate the effectiveness and safety of bromocriptine by vaginal delivery in the treatment of hyperprolactinemia in Chinese female patients, and to provide evidence-based reference for clinic. METHODS: Retrieved from PubMed, The Cochrane Liabrary, Excerpta Medica Database, Chinese Journal Full-text Database, Wanfang Database and China Bxdxiology Medicine disc, randomized controlled trials (RCTs) about bromocriptine oral tablets by vaginal delivery (trial group) vs. bromocriptine by oral administration (control group) in the treatment of bromocriptine in Chinese female patients were collected. After data extraction, quality evaluation of included studies with Cochrane system evaluator manual 5.1.0, Meta-analysis of serum level of Prolactin levels, the rate of menstruation improvement, the rate of pregnancy recovery, the rate of galactorrhea disappearance, the incidence of ADR in digestive tract and the incidence of ADR in nervous system was conducted by using Rev Man 5.1 statistical software. RESULTS: A total of 16 RCTs were included, involving 1 175 patients. The results of Meta-analysis showed that the incidence of ADR in digestive tract [OR=0.14,95%CI(0.09, 0.23),P<0.001] and ADR in nervous system [OR=0.32,95%CI(0.11, 0.90),P=0.03] in trial group were significantly lower than control group, with statistical significance. There was no statistical significance in serum level of PRL [MD=0.24,95%CI (-0.94, 1.41),P=0.69], the rate of menstruation improvement [RD=0.04,95%CI (-0.04, 0.11),P=0.32], the rate of pregnancy recovery [RD=0.01,95%CI (-0.08, 0.10),P=0.84] or the rate of galactorrhea disappearance [RD=0.05,95%CI (-0.03, 0.13),P=0.20] between 2 groups. CONCLUSIONS: Compared with oral administration, bromocriptine by vaginal delivery has no significant difference in therapeutic efficacy but has obvious advantages in the incidence of ADR in digestive tract and in nervous system and better safety. It is suggested to development the special vaginal delivery preparation of bromocriptine.

KEYWORDS Bromocriptine;Vaginal delivery;Oral administration; Systematic evaluation; Effectiveness; Safety; Meta-analysis

高催乳素血症(Hyperprolaceinemia,HPRL)是由多种因素导致垂体前叶嗜酸性细胞分泌过多的血清泌乳素(Prolactin,PRL)引起的下丘脑-垂体-性腺轴功能失调所致的内分泌疾病。该病多发于女性,亦见于男性。HPRL临床上多表现为闭经、溢乳、不孕、习惯性流产、性功能障碍等症[1-2]。不同检测人群中HPRL的发病率不尽相同,在未经选择的正常人群中,HPRL发病率为0.4%;而在计划生育门诊人群中,HPRL的发病率为5%[3]。

引起HPRL的原因可归纳为生理性、药理性、病理性和特发性4类。HPRL的治疗可分为药物、手术和放疗治疗,临床以药物治疗为主。溴隐亭是第一个用于……

登录APP查看全文

猜你喜欢
Meta分析安全性有效性
两款输液泵的输血安全性评估
新染料可提高电动汽车安全性
如何提高英语教学的有效性
甘肃教育(2020年6期)2020-09-11 07:45:28
制造业内部控制有效性的实现
提高家庭作业有效性的理论思考
甘肃教育(2020年12期)2020-04-13 06:24:56
血小板与冷沉淀联合输注在大出血临床治疗中应用的Meta分析
中药熏洗治疗类风湿关节炎疗效的Meta分析
丹红注射液治疗特发性肺纤维化临床疗效及安全性的Meta分析
多索茶碱联合布地奈德治疗支气管哮喘的Meta分析及治疗策略
ApplePay横空出世 安全性遭受质疑 拿什么保护你,我的苹果支付?